LYEL

Lyell Immunopharma, Inc.

Healthcare · Biotechnology

$134.20 sample

-0.80 (-0.59%) 1D

Market cap

$261.5B

Price as of

2026-10-15

Latest filing

8-K

Alerts

8

Price$134.20 -7.87% 3M daily closessample

145.88133.81

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 09INSInsider sell: Director
Oct 05INSInsider sell: Chief Financial Officer
Sep 25INSInsider sell: 10% owner
Sep 22INSInsider sell: Chief Executive Officer
Sep 15INSInsider sell: EVP, Operations
Sep 08INSInsider sell: 10% owner
Aug 28INSInsider buy: Director
Aug 20INSInsider sell: EVP, Operations

Sign up to see the real LYEL record →

Company facts

SEC EDGAR registration

Name: Lyell Immunopharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +37sample, -100 to +100
Reporting currency: USD

Who is positioning in LYEL

sample

Insiders: 18 insider transactions over 90 days, net selling, $727.8M
Congress: 3 members traded over 90 days
Institutions · 13F: 44 funds hold $2.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$11.9B +18.3% y/y

Q4 2024Q3 2026

Inventory$7.0B +19.5% y/y

Q4 2024Q3 2026

Accounts receivable$5.2B +17.2% y/y

Q4 2024Q3 2026

Total debt$14.0B +10.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $105.0B -4.7% 3M
Sample peer B: $97.4B +11.6% 3M
Sample peer C: $225.4B -3.9% 3M
Sample peer D: $88.8B -6.7% 3M
Sample peer E: $249.3B +2.5% 3M